NOX4 antisense oligonucleotide therapy (Ionis Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNOX4 antisense oligonucleotide therapy (Ionis Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionNADPH oxidase 4 inhibitors
TargetsNADPH oxidase 4
Therapy Area/IndicationsPulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIonis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPulmonary Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A